Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Golocdacimab (MEDI6570) in Post-MI Patients with Persistent Inflammation
NCT04610892Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of golocdacimab in coronary heart disease (CHD), myocardial infarction (MI), sponsored by AstraZeneca. Started Nov 2020; status: completed.
02
Drugs
golocdacimab
03
Conditions
coronary heart disease (CHD)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04610892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610892.